Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2004

01-10-2004 | Case Report

Humanized Anti-Interleukin 6 Receptor Antibody Induced Long-term Remission in a Patient with Life-Threatening Refractory Autoimmune Hemolytic Anemia

Authors: Akane Kunitomi, Yoshiteru Konaka, Masato Yagita, Kiyoshi Takatsuki, Norihiro Nishimoto, Tadamitsu Kishimoto

Published in: International Journal of Hematology | Issue 3/2004

Login to get access
Metadata
Title
Humanized Anti-Interleukin 6 Receptor Antibody Induced Long-term Remission in a Patient with Life-Threatening Refractory Autoimmune Hemolytic Anemia
Authors
Akane Kunitomi
Yoshiteru Konaka
Masato Yagita
Kiyoshi Takatsuki
Norihiro Nishimoto
Tadamitsu Kishimoto
Publication date
01-10-2004
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2004
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.04058

Other articles of this Issue 3/2004

International Journal of Hematology 3/2004 Go to the issue

Case Report

Successful Treatment of Tacrolimus (FK506)-Related Leukoencephalopathy with Cerebral Hemorrhage in a Patient Who Underwent Nonmyeloablative Stem Cell Transplantation

OriginalPaper

Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin’s Lymphomas: Results of a Japanese Phase II Study

OriginalPaper

Cytokine-Mediated Cell Survival

OriginalPaper

Nuclear Factor κB Activation and Antiapoptosis in Mucosa-Associated Lymphoid Tissue Lymphoma

Case Report

Aleukemic Leukemia Cutis in a Patient with Philadelphia Chromosome-Positive Biphenotypic Leukemia

Case Report

Successful Unrelated Cord Blood Transplantation Using a Reduced-Intensity Conditioning Regimen in a 6-Month-Old Infant with Congenital Neutropenia Complicated by Severe Pneumonia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits